[Federal Register Volume 72, Number 176 (Wednesday, September 12, 2007)]
[Notices]
[Page 52141]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-18031]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Cardiovascular and Renal Drugs Advisory Committee; Amendment of 
Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of a meeting of the Cardiovascular and Renal Drugs 
Advisory Committee. This meeting was announced in the Federal Register 
of August 14, 2007 (72 FR 45435). The amendment is being made to 
reflect a change in the Date and Time and Agenda portions of the 
meeting. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Cathy A. Miller, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5630 
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), 
Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: 
[email protected], or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area), code 
3014512533. Please call the Information Line for up-to-date information 
on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of August 14, 2007, 
FDA announced that a meeting of the Cardiovascular and Renal Drugs 
Advisory Committee would be held on October 16 and 17, 2007.
    On page 45435, in the second column, the Date and Time portion of 
the document is amended to read as follows:
    Date and Time: The meeting will be held on October 16, 2007, from 8 
a.m. to 5 p.m.
    On page 45435, in the third column, the Agenda portion of the 
document is amended to read as follows:
    Agenda: On October 16, 2007, the committee will discuss regulatory 
considerations for extending the use of phosphate binders from the 
dialysis population (where they are approved) to the pre-dialysis 
population (where no products are approved). The committee will hear 
presentations on this topic from Shire Development, Genzyme Corp., and 
Fresenius Medical Care.

    Dated: September 5, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7-18031 Filed 9-11-07; 8:45 am]
BILLING CODE 4160-01-S